DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The submitted information disclosure statement (IDS) was filed on 04/15/2025. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Specification Objection
The disclosure is objected to because of the following informalities:
Firstly, “The size-reduced population of drug particles possesses each of the PSD parameters: “Dl0 ≤ 1 μM, D50 ≤ 2.2 μM, and D90 ≤ 4.5 μM”.
μm is micrometer.
μM is micromolar.
Wrong μM units for PSD parameters in Specification.
The PSD parameters should be: Dl0 ≤ 1 μm, D50 ≤ 2.2 μm, and D90 ≤ 4.5 μm.
Secondly: “salt in the vehicle is from 0.25% w/v to -5% w/v,”. The specification must demonstrate that the inventor actually possessed the invention at the time of filing. Unless the specification outlines a highly specialized, alternative scientific definition for a negative concentration, the inventor cannot demonstrate possession of something that is physically impossible.
Appropriate corrections are required
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1 and 12 and 2 and 13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 1 and 12 are indefinite because they recite:
“the size-reduced population of drug particles possessing each of the particle size distribution (PSD) parameters: Dl0 ≤ 1 μM, D50 ≤ 2.2 μM, D90 ≤ 4.5 μM,” …
μm is micrometer.
μM is micromolar.
Because the claim introduces particle size distribution in "μM" (micromolar) and later refers to it in "μm" (micrometer), the metes and bounds of the claim are technically unclear. A Person Of Ordinary Skill In The Art (POSITA) would understand it is likely a typo, but as written, it introduces indefiniteness and a lack of antecedent basis (i.e., the "μm" at the end lacks a proper preceding introduction in the same units). The terms "μM" and "μm" render the scope of the particle size distribution boundaries unclear.
Appropriate correction is required.
For examining purposes, examiner will assume that claims 1 and 12: have all PSD in μm as below.
“the size-reduced population of drug particles possessing each of the particle size distribution (PSD) parameters: Dl0 ≤1 μm, D50 ≤ 2.2 μm, D90 ≤ 4.5 μm,”.
Claims 1 and 12 are also indefinite because they recite:
Claim 1,
Starting/Target Suspension Parameters: “The claim requires making a suspension with PSD parameters of: A method for making a suspension consisting essentially of a size-reduced population of drug particles dispersed in a liquid vehicle, the size-reduced population of drug particles possessing each of the particle size distribution (PSD) parameters: Dl0 ≤ 1 μM, D50 ≤ 2.2 μM, D90 ≤ 4.5 μM”,
Reducing Step Parameters: The claim states this is achieved "by reducing particle size so that the PSD parameters of drug particles" are Dl0 ≤ 1 μm, D50 ≤ 2.25 μm, D90 ≤ 4.75 μm”.
For D50 and D90, the reducing step permits larger upper bounds D50 ≤ 2.25 μM, D90 ≤ 4.75 μM than the final suspension requires D50 ≤ 2.2 μM, D90 ≤ 4.5 μM”. Reducing a particle size should result in smaller particles; it is unclear how or whether this guarantees the resulting suspension meets the stricter limits. This creates ambiguity regarding the scope of the claim and whether the reduction step actually results in the claimed suspension.
Appropriate correction is required.
Claim 12,
Starting/Target Suspension Parameters: “The claim requires making a suspension with PSD parameters of: A method for making a suspension consisting essentially of a size-reduced population of drug particles dispersed in a liquid vehicle, the size-reduced population of drug particles possessing each of the particle size distribution (PSD) parameters: Dl0 ≤ 1 μM, D50 ≤ 2.25 μM, D90 ≤ 4.5 μM”,
Reducing Step Parameters: The claim states this is achieved "by reducing particle size so that the PSD parameters of drug particles" are Dl0 ≤ 0.15 μm, D50 ≤ 2.25 μm, D90 ≤ 4.75 μm”.
For D90, the reducing step permits larger upper bounds D90 ≤ 4.5 μM than the final suspension requires D50 ≤ 2.2 μM, D90 ≤ 4.5 μM”. Reducing a particle size results in smaller particles; it is unclear how or whether this guarantees the resulting suspension meets the stricter limits. This creates ambiguity regarding the scope of the claim and whether the reduction step actually should result in the claimed suspension. A particle size distribution cannot grow larger during a size-reduction (milling) process.
Appropriate correction is required.
Claims 2 and 13 are indefinite because they recite: “salt in the vehicle is from 0.25% w/v to -5% w/v,”. A negative concentration of a chemical or physical ingredient (weight per volume) is physically impossible. The scope of the invention is completely unclear and impossible to calculate or infringe.
For examining purpose, the sentence is modified as: “salt in the vehicle is from 0.25% w/v to 5% w/v.”
Appropriate correction is required.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or non-obviousness.
Claim(s) 1-2, 12-13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al. (US 20230085008 A1).
Claims 1 and 12,
Jain et al. teach pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, manufacturing process is also provided, (Abs); oral pharmaceutical compositions and stable nano-suspensions of mifepristone particles, methods for their administration, processes for their production. (0003). Mifepristone is a potent antagonist of steroid hormone receptors. (0004). Mifepristone refers to mifepristone freebase or its pharmaceutically acceptable salts, solvates or hydrates thereof. (0072). Mifepristone is a synthetic steroidal compound (an antiprogestational steroid). Mifepristone can be converted to a pharmaceutically acceptable salt refers to salts by inorganic or organic acids. (0074). And if required, adjust with ortho-phosphoric acid or l N Sodium hydroxide solution. (Tables 1 and 2), to increase solubility. It would be obvious that an acid or a base can be added as needed, which can be applied for other steroid drugs also. The process for preparing nano-suspension of mifepristone comprises:
(a) adding at least one surfactant to the purified water in a suitable container,
(b) adding mifepristone to step (a) and stirred continuously to obtain mifepristone dispersion,
(c) homogenizing the above mifepristone dispersion to obtain mifepristone slurry and
(d) nano-sizing mifepristone slurry in a ball-mill chamber to obtain nano-suspension containing desired particle size of mifepristone. (0135). The pharmaceutical composition comprising a therapeutically effective amount of mifepristone particles and at least one pharmaceutically
acceptable excipient, wherein the mifepristone particles have an average D90 particle size is equal to or less than about 1000 nm, (0030), which mean D50 and D10 ≤ 1000 nm. With D90 ≤ 1000 nm after nanosizing in a ball-mill, then it would have been obvious that drug particles size before nanosizing at least D10 ≥ 1000 nm.
It would have been obvious for one of ordinary skill in the art before the effective filing date of the invention to prepare a steroid drug suspension formulation by adding a surfactant into water with the drug and homogenize the slurry, then nanosizing the slurry to drug particle size to D90 ≤ 1000 nm, taught by Jain et al., since they have proven these excipients will provide a suspension formulation with methods provided above.
With regard to claims 2 and 13,
Jain et al. teach 300 mg of Mifepristone, 8 mg of Sodium lauryl sulphate and 1 mg of Docusate sodium, and in water, (Table 4, (0207), so water can be up to 50, 100 or 200 mL. Mifepristone slurry 20%, (Table 16, 0258) then the water is 2000mL, and surfactants (1+8 mg)/2000mL x 100 = 0.45% w/v. The concentration of chelating agent ranges from about 0.1% to about 1% w/w of total composition. (0181). If required, adjust with ortho-phosphoric acid or lN Sodium hydroxide solution, (Tables 1 and 2), to increase solubility. And the amounts of acid or base in the vehicle will be varied depending on the drug needed to be in freebase or salt form. Mifepristone (MW 430g/mol), so with 300 mg = 0.70 mmol. To converse to salt form with acid, such as acetic acid (MW 60 g/mol), to have 1:1 ratio, 41.9 mg acetic acid is needed, which is 2.1 w/v acid in the vehicle. The amount of acid or base can be varied depending the needed pH of the suspension, the solubility of the drug.
Claim(s) 1, 12 and 3-4, 14-15 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al. (US 20230085008 A1) in view of Hwang et al. (US 20110200678 A1).
The teachings of Jain et al. are described in claims 1 and 12 above.
Jain et al. teach
a surfactant comprising sodium lauryl sulphate and (d) surface stabilizer comprising docusate sodium, (0030), lecithin, polyoxyethylene castor oil, and tyloxapol (0157), poloxamer 188 (0220); citric acid, (0181), if required, adjust with ortho-phosphoric acid or l N Sodium hydroxide solution (Tables 1 and 2).
Jain et al. teach corticosteroids as natural steroid hormones produced by a body (0008), but do not teach corticosteroids as drugs.
Hwang et al. teach
corticosteroids as drugs: Dexamethasone, Dexamethasone sodium phosphate, Dexamethasone palmitate, Hydrocortisone, Hydrocortisone sodium succinate, Prednisolone, Prednisolone acetate, Prednisolone sodium succinate, Prednisolone stearylglycolate, Triamcinolone, Triamcinolone acetonide, Betamethasone sodium phosphate, (0100); and Budesonide (0128).
Acid: Acetic acid. (0042).
Base: Magnesium hydroxide. (0086).
Surfactants: sodium lauryl sulphate, dioctyl sulfosuccinate, lecithin, polyoxyethylene castor oil, poloxamer, Pluronics F68 and tyloxapol. (0137).
It would have been obvious for one of ordinary skill in the art before the effective filing date of the invention to prepare a steroid drug suspension formulation by adding a surfactant as listed above, into water with the drug and homogenize the slurry, then nanosizing the slurry to drug particle size to D90 ≤ 1000 nm, taught by Jain et al., and the drug can be corticostiroids, with surfactants, acids or bases as listed above, taught by Hwang et al., since they have proven these excipients will provide a suspension formulation with methods provided above.
Claim(s) 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al. (US 20230085008 A1) in view of Hwang et al. (US 20110200678 A1).
Jain et al. teach
pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, manufacturing process is also provided. (Abs). Mifepristone is a synthetic steroidal compound (an antiprogestational steroid). oral pharmaceutical compositions and stable nano-suspensions of mifepristone particles, methods for their administration, processes for their production. (0003). Mifepristone can be converted to a pharmaceutically acceptable salt refers to salts by inorganic or organic acids. (0074). And if required, adjust with ortho-phosphoric acid or l N sodium hydroxide solution. (Tables 1 and 2), to increase solubility. It would be obvious that steroid mifepristone steroid and an acid or a base can be added if needed to apply for other drugs to improve solubility. The process for preparing nano-suspension of mifepristone comprises:
(a) adding at least one surfactant to the purified water in a suitable container,
(b) adding mifepristone to step (a) and stirred continuously to obtain mifepristone dispersion,
(c) homogenizing the above mifepristone dispersion to obtain mifepristone slurry and
(d) nano-sizing mifepristone slurry in a ball-mill chamber to obtain nano-suspension containing desired particle size of mifepristone. (0135). The pharmaceutical composition comprising a therapeutically effective amount of mifepristone particles and at least one pharmaceutically
acceptable excipient, wherein the mifepristone particles have an average D90 particle size equal to or less than about 1000 nm, (0030), which mean D50 and D10 ≤ 1000 nm. With D90 ≤ 1000 nm after nanosizing in a ball-mill, then it would have been obvious that drug particles size before nanosizing at least D10 ≥ 1000 nm.
300 mg of mifepristone, 8 mg of Sodium lauryl sulphate and 1 mg of docusate sodium, and in water, (Table 4, (0207), so water can be up to 50, 100 or 200 mL. Mifepristone slurry 20%, (Table 16, 0258) then the water is 2000mL,
and surfactants (1+8 mg)/2000mL x 100 = 0.45%.
The concentration of chelating agent ranges from about 0.1% to about 1% w/w of total composition. (0181).
If required, adjust with ortho-phosphoric acid or l N sodium hydroxide solution, (Tables 1 and 2), to increase solubility. And the amounts of acid or base in the vehicle will be varied depending on the drug needed to be in freebase or salt form. Mifepristone (MW 430g/mol), so with 300 mg = 0.70 mmol. To converse to salt form with acid, such as acetic acid (MW 60 g/mol), to have 1:1 ratio, 41.9 mg acetic acid is needed, which is 2.1 w/v acid in the vehicle. The amount of acid or base can be varied depending the needed pH of the suspension, the solubility of the drug.
a surfactant comprising sodium lauryl sulphate and (d) surface stabilizer comprising docusate sodium, (0030), lecithin, polyoxyethylene castor oil, and tyloxapol (0157), poloxamer 188 (0220); citric acid, (0181), if required, adjust with ortho-phosphoric acid or l N Sodium hydroxide solution (Tables 1 and 2).
Jain et al. teach corticosteroids as natural steroid hormones produced by a body (0008), but do not teach corticosteroids as drugs.
Hwang et al. teach
A group of corticosteroids as drugs: Dexamethasone, Dexamethasone sodium phosphate, Dexamethasone palmitate, Hydrocortisone, Hydrocortisone sodium succinate, Prednisolone, Prednisolone acetate, Prednisolone sodium succinate, Prednisolone stearylglycolate, Triamcinolone, Triamcinolone acetonide, Betamethasone sodium phosphate, (0100); and Budesonide (0128).
Especially Prednisolone acetate. (0100).
Acid: Acetic acid. (0042).
Base: Magnesium hydroxide. (0086).
Surfactants: sodium lauryl sulphate, dioctyl sulfosuccinate, lecithin, polyoxyethylene castor oil, poloxamer, Pluronics F68 and tyloxapol. (0137).
It would have been obvious for one of ordinary skill in the art before the effective filing date of the invention to prepare a steroid drug suspension formulation by adding a surfactant tyloxapol, into water with the drug and homogenize the slurry, then nanosizing the slurry to drug particle size to D90 ≤ 1000 nm, taught by Jain et al., and the drug can be a corticosteroid prednisolone acetate, with surfactant tyloxapol, acids or bases as listed above, taught by Hwang et al., since substituting active ingredient corticosteroid prednisolone acetate into the formulation matrix of steroid mifepristone taught by Jain is a simple substitution of one known element for another to yield a predictable result. Because steroid mifepristone taught by Jain and corticosteroid prednisolone, taught by Hwang belong to the same functional and structural class (steroids/corticosteroids) and share similar utilities, so a Person Having Ordinary Skill in the Art (PHOSITA) would have a reasonable expectation of success in preparing composition of claim 8, with these ranges of concentrations.
Claim(s) 1, 3-4, 8, 14-15 and 5, 7, 9, 11, 16, 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al. (US 20230085008 A1) in view of Hwang et al. (US 20110200678 A1) and further in view of Tada et al. (US 20140328917 A1) and Shaw et al. (US 8367651 B2).
The teachings of Jain et al. and Hwang et al. are described in claims 1, 3-4, 8, 14-15 above.
Jain et al. teach ball-mill (0214), ball-milled at a speed of 1730 RPM at 30° C. for 80
minutes and further milled at 10° C. for 70 minutes, using the conditions set forth in Tables 5 and 6, (0215); Homogenized mifepristone slurry of Composition B was ball-milled at speed of 2500 RPM at 20° C for 140 minutes (see Table 7), (0216); 0.2 mm zirconium beads (see Table 8). Change in zirconium beads size from 0.3 mm to 0.2 mm in milling procedure does not have any significant effect on the particle size distribution of the final nano-suspension. (0217).
Hwang et al. teach prednisolone acetate. (0100).
Jain and Hwang do not teach the beads are from 1 mm to 10 mm in diameter and of
material selected from the group consisting of agate, alumina, ceramic, flint, stainless steel, steel chrome, tungsten carbide, and zirconia, and combinations thereof.
Tada et al. teach one of methods for finely-milling the organic compound to the level of nano-powder with a narrow particle diameter distribution, a method for milling the organic compound by a bead mill using beads made of ceramic, glass, or the like is well known. (0007). The temperature is not particularly limited as far as it can inhibit melting or decomposition of the organic compound, is preferably -50 to 50°C. Time for milling may be determined arbitrarily in considering the organic compound to be milled, the milling apparatus and the like, for example, about 1 to 50 hours. (0074).
Tada et al. do not teach the bead size 1-10mm.
Shaw et al. teach the grinding media comprises beads having a size ranging from 0.05-4 mm. (253).
It would have been obvious that the milling parameters of whether it is mill ball mill, an attritor mill, a vibration mill, a sand mill, or a bead mill, the timing to mill, the temperature to mill, the diameter of the beads, the material of the bead, bead diameters and the rate rpm of milling are varied and interrelated to each other to provide the particle size according to the drug properties, stability and solubility, so one with skill in the art can vary these parameters with the instruments they have, the comprised excipients, the drug they work with, and the particle size they want to have a good suspension composition to prepare a steroid drug suspension formulation by adding a surfactant into water with the drug and homogenize the slurry, then nanosizing the slurry to drug particle size to D90 ≤ 1000 nm, taught by Jain et al.; the drug can be corticostiroids, with surfactants, acids or bases as listed above, taught by Hwang et al., to have bead mill using beads made of ceramic, the temperature can be -50 to 50°C; time for milling can be about 1 to 50 hours, taught by Tada et al. and bead size can be 0.05-4 mm taught by Shaw et all since they have proven these excipients will provide a suspension formulation with methods provided above.
Claim(s) 1, 3-4, 8, 14, 15 and 6, 10, 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jain et al. (US 20230085008 A1) in view of Hwang et al. (US 20110200678 A1) and further in view of Selvaraj et al. (US 20220211630 A1).
The teachings of Jain et al. and Hwang et al. are described in claims 1, 3-4, 8, 14 and 15 above.
Hwang et al. teach Prednisolone acetate. (0100).
Jain et al. and Hwang et al. do not teach the slurry is subjected to the high-pressure homogenization for 5 passes to 250 passes, at from 10,000 PSI to 50,000 PSI and from 4°C to 50°C.
Selvaraj et al. teach an emulsion is formed by homogenization under high pressure and high shear forces. Such homogenization is conveniently carried out in a high-pressure homogenizer, typically operated at pressures in the range of about 3,000 up to 30,000 psi, (0310), during homogenization the emulsion was cooled between 5°C and 10°C and 5-8 passes. (0332).
It would have been obvious that the milling parameters of whether it is mill ball mill, an attritor mill, a vibration mill, a sand mill, or a bead mill, the timing to mill, the temperature to mill, the diameter of the beads, the material of the bead, bead diameters and the rate rpm of milling are varied and interrelated to each other to provide the particle size according to the drug properties, stability and solubility, so one with skill in the art can vary these parameters with the instruments they have, the comprised excipients, the drug they work with, and the particle size they want to have a good suspension composition to prepare a steroid drug suspension formulation by adding a surfactant into water with the drug and homogenize the slurry, then nanosizing the slurry to drug particle size to D90 ≤ 1000 nm, taught by Jain et al., the drug can be corticostiroids, with surfactants, acids or bases as listed above, taught by Hwang et al., and an emulsion is formed by homogenization under high pressure and high shear forces at pressures in the range of about 3,000 up to 30,000 psi, between 5°C and 10°C and 5-8 passes, taught by Selvaraj et al. since they have shown it would be possible to do so.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-18 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of copending Application No. 18/590780 (US 20250268918 A1). Although the claims at issue are not identical, they are not patentably distinct from each other because the method steps are identical and the only differences are the PSD parameters and the presence of acid and base in the instant claims. Since the method steps are the same, it is clear that the starting conditions (PSD parameters) determine the ending PSD parameters; both sets of claims include the same types of drugs and adjustment of the pH via acid and/or base is common in pharmaceutical formulations and such adjustment would have been obvious to one of ordinary skill in the art.
This is a provisional non-statutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NGOC-ANH THI NGUYEN whose telephone number is (571)270-0867. The examiner can normally be reached Monday - Friday 8:00 am.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NGOC-ANH THI NGUYEN/
Examiner, Art Unit 1615
/Robert A Wax/Supervisory Patent Examiner, Art Unit 1615